Overview

Clovis Oncology, Inc. is a United States-based biopharmaceutical company. The Company develops anti-cancer agents. It focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. Its product candidates includes CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine,; CO-1686, an orally available small molecule epidermal growth factor receptor and CO-338, an orally available, small molecule poly (ADP-ribose) polymerase, or PARP.

Endorsements